Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings Beat

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) gapped up before the market opened on Friday after the company announced better than expected quarterly earnings. The stock had previously closed at $18.47, but opened at $20.00. Tandem Diabetes Care shares last traded at $16.6320, with a volume of 731,017 shares changing hands.

The medical device company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.16. The company had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. Tandem Diabetes Care’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.66) earnings per share.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q1 beats and operational upside — Tandem reported Q1 revenue of $247.2M (up 5.5% YoY) and adjusted EPS of -$0.30, both topping Street estimates; gross profit and gross margin improved, and the company said it hit record quarterly pump shipments. Tandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9%
• Positive Sentiment: Margin expansion and pipeline progress — Coverage notes margin improvement driven by lower cost of sales and better gross profit; management highlighted product pipeline advances and a business‑model shift that could support future profitability. TNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shift
• Positive Sentiment: Analyst support — TD Cowen reaffirmed a Buy rating and $28 price target, signaling continued analyst confidence that fundamentals are strengthening. Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained
• Neutral Sentiment: Guidance reaffirmed but unchanged — Management reaffirmed FY2026 revenue guidance around $1.1B (in line with consensus), which removes downside surprise but offers limited upside unless guidance is raised. Tandem Diabetes Care Announces First-Quarter 2026 Financial Results
• Negative Sentiment: Company remains unprofitable with cash‑flow and balance‑sheet considerations — TNDM still reported a net loss and operating loss; operating cash flow weakened YoY and total liabilities rose materially, which keeps execution and capital questions on investors’ radars. Tandem Diabetes Care (TNDM) Stock Rises on Q1 2026 Earnings

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on TNDM shares. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $25.00 price objective (up from $18.00) on shares of Tandem Diabetes Care in a research note on Friday, January 9th. The Goldman Sachs Group reduced their price objective on shares of Tandem Diabetes Care from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Zacks Research raised shares of Tandem Diabetes Care from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price objective (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Finally, Lake Street Capital raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.16.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. State of Alaska Department of Revenue lifted its position in shares of Tandem Diabetes Care by 1.4% during the 4th quarter. State of Alaska Department of Revenue now owns 38,676 shares of the medical device company’s stock valued at $849,000 after acquiring an additional 523 shares during the period. ProShare Advisors LLC lifted its position in shares of Tandem Diabetes Care by 4.6% during the 4th quarter. ProShare Advisors LLC now owns 13,185 shares of the medical device company’s stock valued at $290,000 after acquiring an additional 579 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Tandem Diabetes Care by 80.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 593 shares during the period. Natixis Advisors LLC lifted its position in shares of Tandem Diabetes Care by 1.1% during the 4th quarter. Natixis Advisors LLC now owns 57,021 shares of the medical device company’s stock valued at $1,253,000 after acquiring an additional 617 shares during the period. Finally, Amalgamated Bank lifted its position in shares of Tandem Diabetes Care by 3.5% during the 3rd quarter. Amalgamated Bank now owns 19,617 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 657 shares during the period.

Tandem Diabetes Care Stock Down 10.3%

The company has a current ratio of 2.55, a quick ratio of 2.02 and a debt-to-equity ratio of 2.00. The stock’s 50-day moving average is $21.32 and its 200-day moving average is $20.33. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -5.48 and a beta of 1.64.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.